Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 297 participants.

Also called NCT04798768

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 297 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04798768
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Canada, Czechia, France, Italy, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04798768. Allocation not applicable; no masking; primary purpose treatment. Start 2021-07-20 (actual); primary completion 2024-05-06 (actual). Results posted on 2025-06-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
Acronym
MODULAR ATP
Condition
Tachycardia, Ventricular
Condition
Arrhythmia, Ventricular
Intervention (Device)
mCRM Therapy System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct04798768
Content hash
2a73ceb6ec070fc5dcc0ff9dab81758740d7c84eed058cc2138bfb5ca60c61d8